medicamen

MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | **GSTIN:**07AABCM4302P1ZF

December 30, 2024

To,
National Stock Exchange of India Limited
Listing & Compliance Department
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai - 400051 India.

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Dear Sir/Madam,

Subject: Press Release - Medicamen Organics and Medi Hub Organic Announce Strategic Investment and Manufacturing Collaboration in Nepal

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled - **"Medicamen Organics Strengthens Regional Presence with Investment in Medi Hub Organic's Manufacturing Facility in Nepal".**

A copy of the same will also be uploaded on the Company's website www.medicamenorganics.com.

Kindly take the same on record and display the same on the website of your exchange.

Thanking you.

Yours faithfully,

For and on behalf of
Medicamen Organics Limited

Bal Kishan Gupta
Digitally signed by Bal Kishan Gupta
Date: 2024.12.30 18:51:46 +05'30'

Bal Kishan Gupta
Managing Director
DIN: 00032772

Place: New Delhi

Encl.: as stated above

Medicamen Organics & Medi Hub Organic Announce Strategic Investment & Manufacturing Collaboration In Nepal

New Delhi, India / Kathmandu, Nepal – December 30, 2024 – Medicamen Organics Limited (MOL) (NSE- MEDIORG) a leading manufacturer of pharmaceutical and health products, has announced a strategic partnership with Medi Hub Organic Ltd. (MHOL), a newly incorporated company in Nepal. This collaboration aims to establish a state-of-the-art pharmaceutical manufacturing facility in Nepal that will produce a broad range of pharmaceutical products.

Under the terms of the Memorandum of Understanding (MOU), MOL will invest ₹ 9 Cr (NPR 14.4 Cr) in MHOL to support the construction of the manufacturing facility and meet working capital requirements. As part of the agreement, MOL will hold a 30% stake in MHOL, further reinforcing its commitment to expanding its presence and operations in the region and increase its manufacturing capacities.

The new facility will be constructed to meet CGMP (Current Good Manufacturing Practices) norms and is expected to achieve European quality standards in the near future. This partnership will allow MHOL to leverage MOL's expertise in production and technology, ensuring the supply of high-quality products internationally, while fostering greater self-sufficiency in Nepal's pharmaceutical market.

Moreover, the strategic alliance will promote technology transfer and collaborative procurement efforts, enabling both companies to enhance product offerings and contribute to the growth of the pharmaceutical sector across Nepal, South Asian region and EU.

This partnership marks an important step in the growth trajectory of both MOL and MHOL as they look to address the increasing demand for high-quality healthcare products in strategic markets.

Commenting on the collaboration, Mr. Bal Kishan Gupta, Managing Director said, "This collaboration with Medi Hub Organic Ltd. marks a significant step in our growth strategy. It reflects our commitment to expanding into key markets while building synergies that drive innovation and long-term value. Together, we are poised to meet the evolving needs of the healthcare sector and strengthen our presence across strategic regions."

About Medi Hub Organic Limited (MHOL):

Medi Hub Organic Ltd. (MHOL) is a newly incorporated company based in Kathmandu, Nepal, focused on the production of pharmaceutical products, herbal products, nutraceuticals, and medical devices. With a commitment to meeting the highest manufacturing standards, MHOL aims to become a key player in the growing healthcare sector in Nepal and international market.

About Medicamen Organics Limited

Medicamen Organics Limited stands out as a prominent player in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms. These include Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. The company's diverse offerings serve both state and central government institutions as well as private entities, operating as a contract and third-party manufacturer

The company has two WHO GMP-approved manufacturing facilities located in Haridwar, Uttarakhand, covering an area of 21,536 sq. ft. These facilities feature cutting-edge infrastructure and in-house testing laboratories. A team of skilled and experienced professionals supports a streamlined production process, maintaining consistent quality.

Focused on global expansion, the company's products are distributed not only throughout India but also in African, CIS, and Southeast Asian countries, including Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.

The company's core business model revolves around B2B contract manufacturing, partnering with third-party pharmaceutical companies to market and sell its products. Medicamen Organics also engages actively in government tenders, supplying products to government hospitals, departments, PSUs, and armed forces.

The Company got listed on NSE Emerge in June 28, 2024.

For FY24, the Company has reported Total Income of ₹ 25.29 Cr, with EBITDA of ₹ 4.76 Cr & PAT of ₹ 2.62 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor

Kirin Advisors	**Kirin Advisors Private Limited** Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com